


**Weekly thoughts on the healthcare sector from finnCap's life sciences analysts:  
Mark Brewer and Arshad Ahad**

Market	Last	-1D	-1M	-3M	-12M	YTD	Health	Last	-1D	-1M	-3M	-12M	YTD
MSCI World Index	1,693	0.3%	2.0%	23.1%	1.0%	-5.9%	MSCI World Pharma/Biotech	219	0.4%	0.0%	14.9%	12.7%	2.4%
FTSE All Share	3,427	-0.1%	-0.1%	13.9%	-16.8%	-18.8%	FTSE All Share Health	12,863	0.5%	-2.4%	14.4%	13.5%	-0.1%
AIM All Share	884	-0.1%	0.0%	32.6%	-3.8%	-7.8%	AIM Health	10,739	0.7%	-1.4%	29.8%	2.9%	3.6%
AIM 100	4,528	-0.4%	-0.4%	33.0%	-4.7%	-8.3%							

- The number of excess deaths caused by COVID-19 are falling.
- The number of deaths registered in England and Wales over the week ending 19<sup>th</sup> June fell below the national average (0.7% below) for the first time since lockdown was imposed.


Number of deaths registered by week, England and Wales, 28 December 2019 to 19 June 2020



Source: Office for National Statistics – Deaths registered weekly in England and Wales

## Figure 2: The number of excess deaths involving COVID-19 continued to decrease

Number of deaths registered by week, England and Wales, 28 December 2019 to 19 June 2020




Source: Office for National Statistics – Deaths registered weekly in England and Wales

## Lockdown Latest

- This week Leicester became the first city in Britain to have a local lockdown imposed, after public health officials expressed alarm at a significant rise in COVID-19 cases.
- All non-essential shops closed from Tuesday, with schools to close from today. Residents are to avoid non-essential travel. The planned easing of some restrictions in England from Saturday will not apply to Leicester. The government will review whether it can lift these measures in two weeks time.
- The ability of local leaders to manage new outbreaks is being hampered by gaps in the reporting of data for cities and regions. The government publishes UK-wide figures for COVID-19 cases every day, which includes tests from hospitals and from commercial labs. However, at a subnational level, the total of new daily cases only contain hospital tests. This gap in subnational and regional data has been cited by local political leaders in Leicester as one reason for a delay in locking down the city earlier.
- Going forward, improvements in these processes will be vital in ensuring that the inevitable future local lockdowns are successful, and that they are implemented as early as possible to minimise spikes of infection.

## Leicester's new outbreak is visible only in **pillar 2 data**, which the government does not make public

Daily confirmed Covid-19 cases in Leicester, by testing pillar




Source: Public Health England via the Leicester Mercury  
© FT

## Treatment Update

### Remdesivir price revealed

- For private insurance plans, Gilead has set a list price of \$520 per vial of Remdesivir. The cost for a five-day treatment course using six vials, which most patients are expected to receive, would add up to \$3,120.
- For governments (of developed countries), the price will be lower, at \$390 per vial or \$2,340 per course.
- In developing countries, generic Remdesivir is available from local drugmakers such as Hetero Labs, Cipla and Beximco (AIM: BXP), with costs around \$390 - \$780 per treatment
- In an update last week, the Institute for Clinical and Economic Review (ICER) found that Remdesivir would be cost-effective at around \$4,580 to \$5,080 per patient.
- However, if preliminary data for low-cost dexamethasone are confirmed in a peer-reviewed paper, ICER said Remdesivir's cost should be cut to around \$2,520 - \$2,800.
- ICER has suggested that doctors are viewing dexamethasone as the standard of care for COVID-19, with Remdesivir merely an "adjunct" to it.
- Yesterday it was reported that the US has bought up nearly all global stocks of Remdesivir for the next three months.

## Testing Update



source: Department of Health and Social Care, finnCap

### Remdesivir price revealed

- On 30 June, Yourgene (AIM: YGEN) launched its Clarigene SARS-CoV-2 test for research use only.
- The test is a PCR-based antigen test, with a turnaround time of 80 minutes, following RNA extraction and setup.
- Preliminary data has shown the test to have 100% specificity (although sensitivity figures have not been disclosed).
- A CE marked test is on track for release for the end of July 2020.
- Yourgene already has over 300 laboratory customers and a growing global network of distribution channels in place through which to drive sales of the tests once approved, targeting a pipeline of opportunities.

### Omega Diagnostics\*: COVID-19 Antibody Test Design Freeze

- On 29 June it was announced that Abingdon Health, lead partner of the UK-Rapid Test Consortium (UK-RTC) had attained design freeze for the COVID-19 Rapid Test. Manufacturing protocols will now be transferred to Omega Diagnostics (AIM: ODX) to undertake its own validation work to show equivalent performance and demonstrate that the test can be manufactured at scale.
- An evaluation of pilot batch products showed a test sensitivity of 100% and specificity of 98.4%
- Omega intends to produce 100,000 tests per week, scaling up to 200,000 tests per week by the end of September. Whilst we do not know the price that Omega will receive per test, we have assumed c.£1.50 per foil wrapped device, with a gross margin of c.50%. This would imply peak revenues of c.£0.3m per week


## Avacta\*: Point-of-care Antigen Test Update

- On 24<sup>th</sup> June Avacta (AIM: AVCT) provided a positive update on progress of its SARS-CoV-2 antigen test confirming that Cytiva has produced the first point-of-care strip tests using its Affimers and generated initial data that shows they can detect the spike protein (antigen target) in model samples at concentrations within the clinical range found in saliva of patients with COVID-19.
- With work still to be done to optimise the test, validate the final product and secure regulatory clearances, this programme remains on track for a summer launch.
- If Avacta is able to successfully develop a test(s) in that time frame given the increasing acceptance of potential second waves of infection in global markets and the virus remaining in the community into 2021 and beyond, the valuation upside is considered substantial.


## Track and Trace Update

- The following figure provides a breakdown on UK contact tracing from 25 May – 17 June.
- It is from Anthony Costello, a former WHO director, and member of Independent Sage.
- Costello is very critical of the test and trace system and describes it as “failing”, with most contact traced by public health rather than call centres, and no data on isolation.

**How did NHS Test, Trace & Isolate do from 25 May – 17 June?**




FTSE AIM all share sector performance (1 week)




Source: FactSet

FTSE AIM all share sector performance (1 month)




Source: FactSet

finnLife 50 - Top ten price performers (past week)




Source: FactSet

finnLife 50 - Top ten price performers (past month)




Source: FactSet

finnLife 50 - Bottom ten price performers (past week)



Source: FactSet

finnLife 50 - Bottom ten price performers (past month)



Source: FactSet

## Research reports and comments in the past two weeks

Company	Date	Title	Research Type
Omega Diagnostics*	02-Jul	COVID-19 update – ELISA test approved in India	<a href="#">Morning Note</a>
Cambridge Cognition*	30-Jun	Trading update	<a href="#">Morning Note</a>
Omega Diagnostics*	29-Jun	COVID-19 antibody test design freeze	<a href="#">Morning Note</a>
ANGLE*	25-Jun	Prelims – back in the saddle post-COVID disruption	<a href="#">Company Note</a>
Avacta*	24-Jun	SARS-CoV-2 point-of care antigen test – update	<a href="#">Morning Note</a>
Allergy Therapeutics*	24-Jun	Profit upgrade	<a href="#">Morning Note</a>
Open Orphan*	24-Jun	FY 2019 results	<a href="#">Company Note</a>
ANGLE*	22-Jun	Lockdown easing – analytical and clinical work re-starts	<a href="#">Morning Note</a>
Omega Diagnostics*	22-Jun	£8m fundraise with Open Offer of up to £3m	<a href="#">Company Note</a>

Synaigen*	18-Jun	COVID-19 home setting trial amendments	<a href="#">Morning Note</a>
Avacta*	18-Jun	Potential COVID-19 therapeutic – progress	<a href="#">Morning Note</a>

### Upcoming roadshows and events

Company Name	Ticker	Event Type	Time of Meeting	Date(s) - 1:1's & Group meetings available
SDI Group PLC	SDI	Preliminary Results Roadshow Group Conference Call	11.30-12.25	22-Jul

### An archive of previous Health Matters can be found [here](#).

To UNSUBSCRIBE, please simply reply to that effect.

\*Denotes corporate client of finnCap. This research cannot be classified as objective under finnCap research policy.  
 ^ This company and finnCap have agreed that finnCap will produce and disseminate research and finnCap may receive remuneration in return for this service. This research cannot be classified as objective under the finnCap research policy.

**A marketing communication under FCA Rules, this document has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.**

This research cannot be classified as objective under finnCap Ltd. research policy. Visit [www.finncap.com](http://www.finncap.com)

MAR Research disclosures can be found at <http://www.finncap.com/disclosures>

The recommendation system used for this research is as follows. We expect the indicated target price relative to the FT All Share Index to be achieved within 12 months of the date of this publication. A 'Hold' indicates expected performance relative to this index of +/-10%, a 'Buy' indicates expected outperformance >10% and a 'Sell' indicates expected underperformance of >10%.

Approved and issued by finnCap Ltd. for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to Professional customers. Retail customers who receive this document should ignore it. finnCap Ltd. uses reasonable efforts to obtain information from sources which it believes to be reliable, but it makes no representation that the information or opinions contained in this document are accurate, reliable or complete. Such information and opinions are provided for the information of finnCap Ltd.'s clients only and are subject to change without notice. finnCap Ltd.'s salespeople, traders and other representatives may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to or inconsistent with the opinions expressed herein. This document should not be copied or otherwise reproduced. finnCap Ltd. and any company or individual connected with it may have a position or holding in any investment mentioned in this document or a related investment. finnCap Ltd. may have been a manager of a public offering of securities of this company within the last 12 months, or have received compensation for investment banking services from this company within the past 12 months, or expect to receive or may intend to seek compensation for investment banking services from this company within the next three months. Nothing in this document should be construed as an offer or solicitation to acquire or dispose of any investment or to engage in any other transaction. finnCap Ltd. authorised and regulated by the Financial Conduct Authority, London E14 5HS, and is a member of the London Stock Exchange.